Drugs giant Novartis has hit a snag in its efforts to gain full ownership of eyecare company Alcon, as it faces ongoing resistance from the latter's shareholders. Novartis, which had bought a 25% stake in Alcon from Swiss conglomerate Nestlé in April 2008, announced shortly after the New Year that ...
Please Login to read the full article.
